Navigation Links
Mylan Reports Adjusted Diluted EPS of $0.16 for the Quarter Ended June 30, 2008
Date:8/6/2008

ditionally, current quarter margins were negatively impacted by competition on certain products including amlodipine and oxybutynin during the past twelve months.

The Company reported earnings from operations of $74.0 million for the three months ended June 30, 2008. Excluding the purchase accounting items discussed above, earnings from operations would have been $186.1 million.

For the quarter ended June 30, 2007, Mylan reported earnings from operations of $188.1 million. Excluding certain purchase accounting items, earnings from operations would have been $206.9 million. This represents a current year decrease of $20.8 million or 10.0%, which is the result of increased research and development ("R&D") expense and selling, general and administrative ("SG&A") expense.

R&D expense was $80.8 million for the three months ended June 30, 2008, compared to $31.7 million in the same prior year period. R&D expense includes approximately $40.9 million related to newly acquired entities, all of which was incremental to the comparable prior year period. Excluding this amount, R&D expense increased by $8.1 million or 26% primarily as a result of increased ANDA submissions.

SG&A expense for the three months ended June 30, 2008 was $259.5 million compared to $76.9 million in the same prior year period. SG&A expense includes approximately $152.9 million related to newly acquired entities, all of which was incremental to the comparable prior year period. Excluding this amount, SG&A expense increased by $29.5 million or 38%. The majority of this increase was realized by Corporate and Other, and is the result of costs associated with the integration of Merck Generics, as well as higher payroll and related costs principally attributable to the build-up of additional corporate infrastructure as a direct result of the acquisition.

Interest expense for the current quarter totaled $86.5 million compared to $22.9 million for the three months ended June 30
'/>"/>

SOURCE Mylan Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine news :

1. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
2. Mylan Announces Final FDA Approval for Carvedilol Tablets
3. Mylan Announces Tentative FDA Approval for Topiramate Capsules
4. Mylan Announces Appointment of M. Fabiana Lacerca as Senior Vice President and Chief Compliance Officer
5. Mylan Announces Extension of Tender Offers for Its 5.750% Senior Notes due 2010 and 6.375% Senior Notes due 2015
6. Mylan Announces Appointment of David A. Lillback as Senior Vice President and Global Head of Human Resources
7. Mylan Announces Appointment of Brian Byala as Senior Vice President and Treasurer
8. Mylan Announces Appointment of Didier Barret as President, Europe, Middle East and Africa
9. Mylan Announces Appointment of Harry A. Korman as President, North America
10. Mylan Announces Appointment of John Montgomery as President, Asia Pacific
11. Mylan Announces Management of Specialty Business, Dey L.P.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... 2014 BCC Research reveals in its ... MARKETS , the global market for human antifungal therapeutics ... 2018, with a five-year compound annual growth rate (CAGR) ... at a steady 3.8% CAGR. , Given the current ... coupled with the incidence of increasing mortality and the ...
(Date:9/19/2014)... (PRWEB) September 19, 2014 Ticket Down ... tickets for her 2015 “Honeymoon” Tour. This popular ... for additional savings at the checkout. , Ariana Grande 2015 ... (Independence Event Center) , Feb. 28, 2015: Milwaukee, WI (BMO ... (Xcel Energy Center) , March 03, 2015: Chicago, IL (Allstate ...
(Date:9/19/2014)... An ultrasensitive biosensor made from the wonder material graphene ... increased risk of developing cancer. , The biosensor ... more sensitive than bioassay tests currently in use, and ... minutes, opening up the possibility of a rapid, point-of-care ... presented today, 19 September, in IOP Publishing,s journal ...
(Date:9/19/2014)... Follow us on LinkedIn ... detection and quantification of the presence of antigens ... steady expansion in immunodiagnostics and technological advancements in ... market has evolved remarkably well over the years. ... cardio-vascular ailments, infectious diseases, allergy and cancer, continue ...
(Date:9/19/2014)... 19, 2014 Recent financial data ... industry increased their sales by 7% in the last ... trucking industry can be used as a bellwether to ... whole. This data has been proven to show trends ... freight transportation. Other non-trucking data is largely influenced by ...
Breaking Medicine News(10 mins):Health News:Global Market for Human Antifungal Therapeutics to Reach Nearly $13.9 Billion in 2018; Over-The-Counter (OTC) Segment Growing At 3.8% CAGR 2Health News:Global Market for Human Antifungal Therapeutics to Reach Nearly $13.9 Billion in 2018; Over-The-Counter (OTC) Segment Growing At 3.8% CAGR 3Health News:Ariana Grande Tickets in Miami, Philadelphia, Chicago, Saint Paul, Fairfax, Uncasville, Orlando, San Jose, New York, Detroit, San Antonio, Pittsburgh, Atlanta & Dallas 2Health News:Ariana Grande Tickets in Miami, Philadelphia, Chicago, Saint Paul, Fairfax, Uncasville, Orlando, San Jose, New York, Detroit, San Antonio, Pittsburgh, Atlanta & Dallas 3Health News:Ariana Grande Tickets in Miami, Philadelphia, Chicago, Saint Paul, Fairfax, Uncasville, Orlando, San Jose, New York, Detroit, San Antonio, Pittsburgh, Atlanta & Dallas 4Health News:Graphene sensor tracks down cancer biomarkers 2Health News:Growing Preference for Non-Invasive Diagnostics Spurs Growth in the Global Immunoassay Systems Market, According to New Report by Global Industry Analysts, Inc. 2Health News:Growing Preference for Non-Invasive Diagnostics Spurs Growth in the Global Immunoassay Systems Market, According to New Report by Global Industry Analysts, Inc. 3Health News:Growing Preference for Non-Invasive Diagnostics Spurs Growth in the Global Immunoassay Systems Market, According to New Report by Global Industry Analysts, Inc. 4Health News:LeaseQ Announces Good News For The Truck Leasing Industry As Truck Rentals In The U.S Continues to Gain Traction 2Health News:LeaseQ Announces Good News For The Truck Leasing Industry As Truck Rentals In The U.S Continues to Gain Traction 3
... CORONA, Calif., Feb. 19 Watson Pharmaceuticals,Inc. (NYSE: ... branded pharmaceuticals,today reported financial results for its fourth quarter ... Fourth Quarter 2008 Results , ... increased $17.9 million or 3,percent from the fourth quarter ...
... to Vote Gold Card and Reject Dissidents, Director Slate ... (Nasdaq: LCAV ) today announced that it ... it urges support for Company management and its Board ... letter follows: To My Fellow Stockholders:Your LCA-Vision executive Team ...
... Full-Year 2009 OutlookVIRGINIA BEACH, Va., Feb. 19, 2009 AMERIGROUP ... net income for the fourth quarter of 2008 increased 20.0% ... income of $31.1 million, or $0.57 per diluted share, for ... December 31, 2008, the Company,s net loss was $50.7 million, ...
... foundation, announces its series of dental related health care reports under ... ... Springs, CO (PRWEB) February 19, 2009 -- Toxic Elements Research Foundation ... related health care reports under the title of ,Elements of Disease., ...
... greenhouse gas emissions, Oregon will face some $3.3 billion ... tab of about 4 percent of annual household income ... University of Oregon,s Climate Leadership Initiative,s Program on Climate ... Economics is guided by a steering committee of 19 ...
... Sessions begin Saturday, March 14 at 10 a.m. SAN FRANCISCO, ... and Wellness Center , is excited to bring back its ... San Francisco. Starting Saturday, March 14 at 10 a.m., ... Park or in the Presidio (near the Lyon Street Stairs) ...
Cached Medicine News:Health News:Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results; Provides 2009 Outlook 2Health News:Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results; Provides 2009 Outlook 3Health News:Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results; Provides 2009 Outlook 4Health News:Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results; Provides 2009 Outlook 5Health News:Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results; Provides 2009 Outlook 6Health News:Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results; Provides 2009 Outlook 7Health News:Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results; Provides 2009 Outlook 8Health News:Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results; Provides 2009 Outlook 9Health News:Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results; Provides 2009 Outlook 10Health News:Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results; Provides 2009 Outlook 11Health News:Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results; Provides 2009 Outlook 12Health News:Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results; Provides 2009 Outlook 13Health News:Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results; Provides 2009 Outlook 14Health News:Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results; Provides 2009 Outlook 15Health News:Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results; Provides 2009 Outlook 16Health News:Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results; Provides 2009 Outlook 17Health News:Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results; Provides 2009 Outlook 18Health News:LCA-Vision Reports Tangible Results from Business Strategy 2Health News:LCA-Vision Reports Tangible Results from Business Strategy 3Health News:LCA-Vision Reports Tangible Results from Business Strategy 4Health News:LCA-Vision Reports Tangible Results from Business Strategy 5Health News:AMERIGROUP Reports Q4 Net Income of $37.3 Million or $0.70 Per Diluted Share 2Health News:AMERIGROUP Reports Q4 Net Income of $37.3 Million or $0.70 Per Diluted Share 3Health News:AMERIGROUP Reports Q4 Net Income of $37.3 Million or $0.70 Per Diluted Share 4Health News:AMERIGROUP Reports Q4 Net Income of $37.3 Million or $0.70 Per Diluted Share 5Health News:AMERIGROUP Reports Q4 Net Income of $37.3 Million or $0.70 Per Diluted Share 6Health News:AMERIGROUP Reports Q4 Net Income of $37.3 Million or $0.70 Per Diluted Share 7Health News:AMERIGROUP Reports Q4 Net Income of $37.3 Million or $0.70 Per Diluted Share 8Health News:AMERIGROUP Reports Q4 Net Income of $37.3 Million or $0.70 Per Diluted Share 9Health News:AMERIGROUP Reports Q4 Net Income of $37.3 Million or $0.70 Per Diluted Share 10Health News:AMERIGROUP Reports Q4 Net Income of $37.3 Million or $0.70 Per Diluted Share 11Health News:AMERIGROUP Reports Q4 Net Income of $37.3 Million or $0.70 Per Diluted Share 12Health News:AMERIGROUP Reports Q4 Net Income of $37.3 Million or $0.70 Per Diluted Share 13Health News:AMERIGROUP Reports Q4 Net Income of $37.3 Million or $0.70 Per Diluted Share 14Health News:AMERIGROUP Reports Q4 Net Income of $37.3 Million or $0.70 Per Diluted Share 15
(Date:9/19/2014)... EASTON, Mass. , Sept. 19, 2014 /PRNewswire/ ... "Company") today announced it has received and approved ... Barozyme HT48 instruments and has begun to manufacture ... the first instrument will be ready for shipment ... be built and released at a rate of ...
(Date:9/19/2014)... , Sept. 19, 2014  BioSpecifics Technologies Corp. (NASDAQ: ... collagenase-based products marketed as XIAFLEX ® in the U.S. ... BioSpecifics, President, Tom Wegman , will present a corporate ... the Biotech Industry Conference. The presentation will ... EDT at the Millennium Broadway Hotel in New ...
(Date:9/19/2014)... -- Aufgrund der enormen Nachfrage seines ... aktualisiert, der jetzt auch die Jahre 2014 - ... pharmaserialisation.com , zeigt die Serialisierungsanforderungen weltweit und den ... Für international tätige Unternehmen geht es ... sondern darum, "wann" sie die neu in Kraft ...
Breaking Medicine Technology:Pressure BioSciences Announces Completion of the First Phase of Its Commercialization Plan for the Barozyme HT48, the Company's Recently Released High Throughput PCT-based Instrument System 2Pressure BioSciences Announces Completion of the First Phase of Its Commercialization Plan for the Barozyme HT48, the Company's Recently Released High Throughput PCT-based Instrument System 3BioSpecifics Technologies Corp. to Present at the 21st Annual BioCentury NewsMakers in the Biotech Industry Conference 2Pharma IQ stellt weltweite Serialisierungsfristen in seinen Countdown-Kalender 2014 - 2018 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: